COR-1167 / Corteria Pharmaceuticals - LARVOL DELTA

CRAFT-WHF: CRF2 Agonist for the Treatment of Worsening Heart Failure (clinicaltrials.gov) - P2 | N=300 | Suspended | Sponsor: Corteria Pharmaceuticals | Active, not recruiting ➔ Suspended

Trial suspension • Cardiovascular • Congestive Heart Failure • Heart Failure

CRAFT-WHF: CRF2 Agonist for the Treatment of Worsening Heart Failure (clinicaltrials.gov) - P2 | N=300 | Active, not recruiting | Sponsor: Corteria Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure

COR1167-102: A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167 (clinicaltrialsregister.eu) - P1 | N=20 | Not yet recruiting | Sponsor: Corteria Pharmaceuticals

New P1 trial • Cardiovascular • Heart Failure

In ovine heart failure transcriptome analysis showed that COR-1167 (CRF2 agonist) improved energetics and structure with less hypoxia and injury in association with elevated cardiac output (ESC 2026) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

First in class CRF2 receptor agonist COR-1167, reduces decompensation, improves exercise capacity, cardiac and renal function on top of Empagliflozin in the ZSF-1 rat model of worsening heart failure with preserved ejection fraction (AHA 2025) - "Urocortin-2 (UCN-2) peptide which is part of the corticotropin-releasing factor (CRF) family, is a paracrine CRF2 receptor agonist that protects heart and kidney function in various HF models and in HF patients. On a background of volume overload and Empa treatment, daily s.c. delivery of COR-1167 maintained CO, rapidly ameliorated decompensation and deteriorating heart and kidney function in ZSF-1 rats. Chronic CRF2 agonism with COR-1167 is a potential new therapy to treat patients with WHF and preserved ejection fraction."

Late-breaking abstract • Preclinical • Cardiovascular • Congestive Heart Failure • Glomerulonephritis • Heart Failure • KIM1

CRAFT-WHF: CRF2 Agonist for the Treatment of Worsening Heart Failure (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Corteria Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure